Clinical trials: Cardiac
Central Sleep Apnea, Heart Failure
French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10CS): Predictive Factors of Poor Compliance (FACE)
The purpose of this study is to determine the predictive factors of poor compliance to sleep disordered breathing therapy in chronic heart failure patients treated for central sleep apnea.
- Trial name
- FACE (NCT02356367)
- Testing
- telemonitoring
- Where
- 3 sites in France
- Sponsor
- ResMed
Congenital Heart Diseases
Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
1. Explore the efficacy of Ulinastatin use in improving post-operative pulmonary insufficiency and safety in pediatric patients undergoing scheduled CPB open heart surgery to treat Complex Congenital Heart Disease 2.
- Trial name
- NCT02527811
- Testing
- Ulinastatin
- Where
- 5 sites in China
- Volunteers
- 450 people
- Sponsor
- Techpool Bio-Pharma Co., Ltd.
Healthy Volunteers
Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects
This is a single-center, randomized, partially double-blind, placebo and active-controlled, 4-period crossover design thorough QT/QTc (TQT) clinical study to evaluate the effects of ziresovir on cardiac repolarization in healthy…
- Trial name
- NCT06591845
- Testing
- Ziresovir 125 mg, Ziresovir 500 mg, Moxifloxacin hydrochloride tablet 400 mg
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Hypertriglyceridemia, Cardiovascular Diseases
Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
This was a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 678354 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03385239
- Testing
- ISIS 678354
- Where
- 31 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Akcea Therapeutics
Coronary Artery Disease, Myocardial Infarction
Clinical Evaluation of Radiation Reduction for Optimized Safety
The primary objective of this study is to determine whether a reduced radiation protocol (RRP) in which angiograms are acquired at ultralow radiation doses and then processed using spatiotemporal enhancement software can produce…
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Coronary Disease, Coronary Stenosis
- Trial name
- CERROS (NCT06348875)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Angiowave Imaging
Atrial Fibrillation
Safety Study of Tecadenoson to Treat Atrial Fibrillation
Assess the tolerability and safety of a rapid bolus of tecadenoson at different dose levels when given alone and in combination with a beta-blocker (esmolol) in patients with atrial fibrillation to control rapid heart rate.
- Trial name
- NCT00713401
- Testing
- Tecadenoson, Esmolol
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Stroke, Prevention and Control
An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres
describe the sociodemographic and clinical characteristics of patients diagnosed with non-valvular atrial fibrillation (NVAF) at risk of stroke or systemic embolism on anticoagulant therapy who have changed their therapeutic…
- Conditions
- Stroke, Prevention and Control, Atrial Fibrillation
- Trial name
- SILVER-AP (NCT02470767)
- Testing
- Direct Oral Anticoagulant (DOAC)
- Where
- Spain
- Volunteers
- 792 people
- Sponsor
- Bayer
Aortic Stenosis, Aortic Insufficiency
Freedom SOLO Stentless Heart Valve Study
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.
- Trial name
- SOLO (NCT01115907)
- Testing
- Freedom SOLO Stentless Heart Valve
- Where
- 15 sites in United States, Canada
- Volunteers
- 251 people
- Sponsor
- Sorin Group USA, Inc.
Coronary Artery Disease
Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent system in the treatment of patients with de novo coronary artery lesions.
- Trial name
- NCT02360709
- Testing
- CRE8 sirolimus-eluting stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- CID S.p.A.
Atrial Fibrillation
nContactSurgical Numeris-AF Tethered Coagulation System for Treatment of Persistent & LSP AF
This is a multi center, non-randomized, prospective, open label, clinical trial evaluating the safety and efficacy of the nContact Surgical Numeris-AF Tethered Coagulation System when used to treat patients with persistent and…
- Trial name
- NCT00950092
- Testing
- Numeris-AF Tethered Coagulation System with VisiTrax
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- nContact Surgical Inc.
Diabetes, Coronary Artery Disease
Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global
To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abluminus DES+ sirolimus- eluting stents (SES) versus XIENCE Everolimus-Eluting…
- Conditions
- Diabetes, Coronary Artery Disease, Acute Coronary Syndrome
- Trial name
- ABILITY (NCT04236609)
- Testing
- Abluminus DES+ Sirolimus Eluting Stent System (SES), XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)
- Where
- 90 sites in Australia, Austria and 19 more
- Volunteers
- 3,050 people
- Sponsor
- Concept Medical Inc.
Bleeding
Phase II Study to Compare MDCO-2010 vs Placebo and Tranexamic Acid in Patients Undergoing Cardiac Surgery
The objective of this study is to determine the dose response relationship regarding blood loss, PK, PD and clinical outcomes of MDCO-2010 in comparison to placebo and tranexamic acid in patients undergoing primary cardiac…
- Trial name
- NCT01530399
- Testing
- MDCO 1, MDCO 2, MDCO 3
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 44 people
- Sponsor
- The Medicines Company
Heart Failure, Congestive
Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure
Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure
- Trial name
- RELAX-AHF (NCT00520806)
- Testing
- Relaxin
- Where
- 3 sites in United States, Israel
- Volunteers
- 1,161 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Heart Transplant
Donors After Circulatory Death Heart Trial
To evaluate the effectiveness of the OCS Heart System to resuscitate, preserve and assess hearts donated after circulatory death for transplantation to increase the pool of donor hearts available for transplantation.
- Trial name
- NCT03831048
- Testing
- OCS Heart System, Cold Storage
- Where
- 25 sites in United States
- Volunteers
- 180 people
- Sponsor
- TransMedics
Cardiovascular Diseases, Smoking
Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease
The purpose of this study is to demonstrate improvement in flow mediated dilation (FMD), a functional endpoint associated with the progression of atherosclerosis, when switching from cigarettes to the Tobacco Heating System (THS)…
- Conditions
- Cardiovascular Diseases, Smoking, Tobacco Use, Peripheral Arterial Disease
- Trial name
- NCT05566678
- Testing
- Cigarette, THS, Smoking Abstinence
- Sponsor
- Philip Morris Products S.A.
Heart Failure
Jarvik 2000 Heart as a Bridge to Cardiac Transplantation - Pivotal Trial
The purpose of the study is to determine the safety and effectiveness of the Jarvik 2000 Heart as a bridge to heart transplantation in end-stage heart failure patients who are approved heart transplant candidates.
- Trial name
- NCT00591799
- Testing
- The Jarvik 2000 Ventricular Assist System
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Jarvik Heart, Inc.
Unstable Angina, Myocardial Infarction
SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes
Patients experiencing a mild heart attack will receive one of two medications which thin the blood to discern which is superior.
- Conditions
- Unstable Angina, Myocardial Infarction, Myocardial Ischemia
- Trial name
- NCT00043784
- Testing
- enoxaparin
- Where
- United States
- Volunteers
- 8,000 people
- Sponsor
- Sanofi
Acute Myocardial Infarction (AMI)
Artificial Intelligence Scalable Solution for ST Myocardial Infarction
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction…
- Trial name
- ASSIST (NCT06939738)
- Where
- 5 sites in Portugal, Spain
- Volunteers
- 489 people
- Sponsor
- Idoven 1903 S.L.
Hemorrhage, Atrial Fibrillation, Postoperative
Prevention of Retained-Blood Outcomes With Active Clearance Technology
Postoperative bleeding is a common consequence after heart surgery which can significantly impact outcomes and costs . When bleeding occurs, reliable postoperative blood evacuation of the pleural, mediastinal and pericardial…
- Trial name
- NCT02145858
- Testing
- Blood drainage post cardiac surgery using PleuraFlow System
- Where
- 2 sites in United States
- Volunteers
- 891 people
- Sponsor
- ClearFlow, Inc.
Atrial Fibrillation
Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation
Atrial fibrillation is the most common serious abnormal heart rhythm affecting about 2% to 3% of the population, being associated with a 1.5- to 1.9-fold higher risk of death.
- Trial name
- NCT02614521
- Testing
- pulmonary veins ablation's successful outcome
- Where
- Greece
- Sponsor
- Elpen Pharmaceutical Co. Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.